+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Plasma Derived Therapies Market (Immunoglobulin, Hemophilia, Specialty, and Albumin): Insights & Forecast with Potential Impact of COVID-19 (2022-2026)

  • PDF Icon

    Report

  • 106 Pages
  • April 2022
  • Region: Global
  • Koncept Analytics
  • ID: 5575701
10% Free customization
10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

The global plasma derived therapy market is anticipated to reach US$50.70 billion in 2026, growing at a CAGR of 7.20% during the period spanning 2022-2026. The growth in the market has been driven by factors like rising geriatric population, increasing prevalence of genetic disorders, government initiatives, rising demand for albumin, escalating use of plasma proteins in pharmaceuticals, increasing usage of immunoglobulin, surging autoimmune disorders. The market is expected to face certain challenges such as high cost and stringent regulations. To overcome these challenges, the market would witness some key trends like technological advancements, rising demand for health insurance, escalating use of therapeutic protein drugs, and increasing adoption of plasma therapy in neurology.



The global plasma derived therapy market can be segmented as follows: Immunoglobulin, Hemophilia, Specialty, and Albumin. Immunoglobulin held a larger share of the market in 2021. Due to the rising use in primary immunodeficiency and neurological applications, the immunoglobulins market is predicted to grow. For example, Grifols, S.A., a pharmaceutical and chemical company, launched HyperHEP B, a new formulation of immune globulin derived from human plasma for hepatitis B postexposure prophylaxis, in June 2021, propelling the industry forward.

The global plasma derived therapy market by region can be segmented into the following: North America, Europe, Asia Pacific, and LAMEA. North America held a larger share of the market in 2021. Growing use of immunoglobulins in various therapeutic domains, increased plasma collection (and the number of plasma collection facilities), and rising prevalence of respiratory disorders and alpha-1-antitrypsin deficiency are all driving market expansion (AATD).

Scope of the report

  • The report provides a comprehensive analysis of the global plasma derived therapy market, segmented into Immunoglobulin, Hemophilia, Specialty, and Albumin.
  • The major regional markets North America, Europe, Asia Pacific, and LAMEA have been analyzed.
  • The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
  • The competitive landscape of the market, along with the company profiles of leading players (ADMA Biologics, Kedrion, Grifols, Takeda Pharmaceutical Company, Octapharma, and CSL Limited) are also presented in detail.

Key Target Audience

  • Plasma collection Centers
  • End Users (Hospital, Medical centers, Clinical Institutes)
  • Healthcare Consulting Firms
  • Investment Banks
  • Government Bodies & Regulating Authorities
Frequently Asked Questions about the Plasma Derived Therapies Market

What is the estimated value of the Plasma Derived Therapies Market?

The Plasma Derived Therapies Market was estimated to be valued at $38.39 Billion in 2022.

What is the growth rate of the Plasma Derived Therapies Market?

The growth rate of the Plasma Derived Therapies Market is 7.2%, with an estimated value of $50.7 Billion by 2026.

What is the forecasted size of the Plasma Derived Therapies Market?

The Plasma Derived Therapies Market is estimated to be worth $50.7 Billion by 2026.

Who are the key companies in the Plasma Derived Therapies Market?

Key companies in the Plasma Derived Therapies Market include CSL Limited, Grifols, Takeda Pharmaceutical Company, Octapharma AG and ADMA Biologics.

Table of Contents

1. Market Overview
1.1 Plasma-Derived Therapies
1.1.1 Introduction
1.2 Segments of Plasma Derived Therapies
1.2.1 Immunoglobulin
1.2.2 Hemophilia
1.2.3 Albumin
1.3 Plasma Derived Therapy Production Process
1.4 Value Chain of Plasma Derived Therapy
1.5 Advantages of Plasma Derived Therapy for Patients
2. Impact of COVID-19
2.1 Impact of COVID-19 on HealthCare Market
2.2 Impact of COVID-19 on Plasma
2.3 Impact of COVID-19 on Plasma Collection
2.4 Prevalence of COVID-19
3. Global Market Analysis
3.1 Global Plasma Derived Therapy Market by Value
3.2 Global Plasma Derived Therapy Market Forecast by Value
3.3 Global Plasma Derived Therapy Market by Segments
3.3.1 Global Immunoglobulin Plasma Derived Therapy Market by Value
3.3.2 Global Immunoglobulin Plasma Derived Therapy Market Forecast by Value
3.3.3 Global Immunoglobulin Plasma Derived Therapy Market by Segments
3.3.4 Global Immunoglobulin Plasma Derived Therapy Market Forecast by Segments
3.3.5 Global Hemophilia Plasma Derived Therapy Market by Value
3.3.6 Global Hemophilia Plasma Derived Therapy Market Forecast by Value
3.3.7 Global Hemophilia Plasma Derived Therapy Market Forecast by Segments
3.3.8 Global Hemophilia Plasma Derived Therapy Market Forecast by Segments
3.3.9 Global Specialty Plasma Derived Therapy Market by Value
3.3.10 Global Specialty Plasma Derived Therapy Market Forecast by Value
3.3.11 Global Albumin Plasma Derived Therapy Market by Value
3.3.12 Global Albumin Plasma Derived Therapy Market Forecast by Value
3.4 Global Plasma Derived Therapy Market by Region
4. Regional Market Analysis
4.1 North America
4.1.1 North America Plasma Derived Therapy Market Forecast by Value
4.1.2 North America Plasma Derived Therapy Market by Region
4.1.3 The US Plasma Derived Therapy Market Forecast by Value
4.2 Europe
4.2.1 Europe Plasma Derived Therapy Market Forecast by Value
4.3 Asia Pacific
4.3.1 Asia Pacific Plasma Derived Therapy Market Forecast by Value
4.4 LAMEA
4.4.1 LAMEA Plasma Derived Therapy Market Forecast by Value
5. Market Dynamics
5.1 Growth Drivers
5.1.1 Rising Geriatric Population
5.1.2 Increasing Prevalence of Genetic Disorders
5.1.3 Government Initiatives
5.1.4 Rising Demand for Albumin
5.1.5 Escalating Use of Plasma Proteins in Pharmaceuticals
5.1.6 Increasing Usage of Immunoglobulin
5.1.7 Suring Autoimmune Disorders
5.2 Key Trends and Developments
5.2.1 Technological Advancements
5.2.2 Rising Demand for Health Insurance
5.2.3 Escalating Use of Therapeutic Protein Drugs
5.2.4 Increasing Adoption of Plasma Therapy in Neurology
5.3 Challenges
5.3.1 High Cost
5.3.2 Stringent Regulations
6. Competitive Landscape
6.1 Global Market
6.1.1 Revenues Comparison- Key Players
6.1.2 Market Capitalization Comparison- Key Players
6.1.3 Research & Development Expenses Comparison - Key Players
6.1.4 Selected Drugs Approved or In Development for AATD- Key Players
6.1.5 Plasma Market Share- Key Players
6.1.6 Immunoglobulin Market Share- Key Players
6.1.7 Albumin Market Share- Key Players
6.2 The US and Europe Market
6.2.1 The US and EU Collection Centers Key Players
6.3 The US Market
6.3.1 Acquisitions of U.S.-based Plasma Centers - Key Players
7. Company Profiles
7.1 CSL Limited
7.1.1 Business Overview
7.1.2 Financial Overview
7.1.3 Business Strategies
7.2 Grifols
7.2.1 Business Overview
7.2.2 Financial Overview
7.2.3 Business Strategies
7.3 Takeda Pharmaceutical Company
7.3.1 Business Overview
7.3.2 Financial Overview
7.3.3 Business Strategies
7.4 Octapharma AG
7.4.1 Business Overview
7.4.2 Financial Overview
7.4.3 Business Strategies
7.5 Kedrion
7.5.1 Business Overview
7.5.2 Financial Overview
7.5.3 Business Strategies
7.6 ADMA Biologics
7.6.1 Business Overview
7.6.2 Financial Overview
7.6.3 Business Strategies
List of Figures
  • Segments of Plasma Derived Therapies
  • Plasma Derived Therapy Production Process
  • Value Chain of Plasma Derived Therapy
  • Advantages of Plasma Derived Therapy for Patients
  • Volume of Plasma Collected in the US and Number of US-based Collection Centres (2016- 2020)
  • Rising Coronavirus Cases in the US (Feb 2020- Mar 2022)
  • Global Plasma Derived Therapy Market by Value (2017-2021)
  • Global Plasma Derived Therapy Market Forecast by Value (2022-2026)
  • Global Plasma Derived Therapy Market by Segments (2021)
  • Global Immunoglobulin Plasma Derived Therapy Market by Value (2017-2021)
  • Global Immunoglobulin Plasma Derived Therapy Market Forecast by Value (2022-2026)
  • Global Immunoglobulin Plasma Derived Therapy Market by Segments (2021)
  • Global Immunoglobulin Plasma Derived Therapy Market Forecast by Segments (2021-2026)
  • Global Hemophilia Plasma Derived Therapy Market by Value (2017-2021)
  • Global Hemophilia Plasma Derived Therapy Market Forecast by Value (2022-2026)
  • Global Hemophilia Plasma Derived Therapy Market by Segments (2021)
  • Global Hemophilia Plasma Derived Therapy Market Forecast by Segments (2021-2026)
  • Global Specialty Plasma Derived Therapy Market by Value (2017-2021)
  • Global Specialty Plasma Derived Therapy Market Forecast by Value (2022-2026)
  • Global Albumin Plasma Derived Therapy Market by Value (2017-2021)
  • Global Albumin Plasma Derived Therapy Market Forecast by Value (2022-2026)
  • Global Plasma Derived Therapy Market by Region (2021)
  • North America Plasma Derived Therapy Market Forecast by Value (2020-2026)
  • North America Plasma Derived Therapy Market by Region (2021)
  • The US Plasma Derived Therapy Market Forecast by Value (2020-2026)
  • Europe Plasma Derived Therapy Market Forecast by Value (2020-2026)
  • Asia Pacific Plasma Derived Therapy Market Forecast by Value (2020-2026)
  • LAMEA Plasma Derived Therapy Market Forecast by Value (2020-2026)
  • Global Geriatric Population (2016-2020)
  • Diagnosed Prevalence Cases of Rheumatoid Arthritis in Eight Major Markets (2019-2029)
  • The U.S. Health and Medical Insurance (2018-2022)
  • Key Players - Plasma Market Share (2021)
  • Key Players - Immunoglobulin Market Share (2021)
  • Key Players - Albumin Market Share (2021)
  • Key Players -The US and EU collection Centers (2021)
  • CSL Limited Operating Revenue and Net Profit (2017-2021)
  • CSL Limited Operating Revenue by Segment (2021)
  • CSL Limited Operating Revenue by Region (2021)
  • Grifols Net Revenues and Group Profit (2017-2021)
  • Grifols Net Revenue by Segments (2021)
  • Grifols Net Revenues by Regions (2021)
  • Takeda Pharmaceutical Company Revenue and Net Profit (2017-2021)
  • Takeda Pharmaceutical Company Revenue by Therapeutic Area (2021)
  • Takeda Pharmaceutical Company Revenue by Region (2021)
  • Octapharma Revenues and Net Profit of the Year (2017-2021)
  • Kedrion Revenues from Sales & Services and Net Result for the Period (2016-2020)
  • Kedrion Revenues from Sales & Services by Regions (2021)
  • ADMA Revenues and Net Loss (2017-2021)
  • ADMA Revenues by Segment (2021)
  • ADMA Revenues by Region (2021)

List of Tables
  • Key Players - Revenues Comparison (2020/2021)
  • Key Players - Market Capitalization Comparison (2021)
  • Key Players - Research & Development Expenses Comparison (2020/2021)
  • Key Players - Selected Drugs Approved or In Development for AATD
  • Key Players - Acquisitions of U.S.-based Plasma Centers

Companies Mentioned

  • CSL Limited
  • Grifols
  • Takeda Pharmaceutical Company
  • Octapharma AG
  • Kedrion
  • ADMA Biologics